Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia.
Publication/Presentation Date
6-1-2001
Abstract
A 72-year-old male who was given abciximab for unstable angina developed acute profound thrombocytopenia with a platelet count nadir of 6,000/mm3. He was treated with steroids and platelet transfusion. Four days later, he underwent coronary angioplasty after pretreatment with eptifibatide without development of thrombocytopenia. This suggests that the development of thrombocytopenia with abciximab is not necessarily a contraindication to subsequent use of glycoprotein (GP) IIb/IIIa receptor antagonists. Eptifibatide may be an appropriate consideration in high-risk patients who would benefit from a GP IIb/IIIa receptor antagonist, in spite of acute profound thrombocytopenia due to abciximab therapy.
Volume
13
Issue
6
First Page
471
Last Page
473
ISSN
1042-3931
Published In/Presented At
Rao, J., & Mascarenhas, D. A. (2001). Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia. The Journal of invasive cardiology, 13(6), 471–473.
Disciplines
Medicine and Health Sciences
PubMedID
11385174
Department(s)
Department of Medicine
Document Type
Article